TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30107042

Group type: EXPERIMENTAL
Intervention: Calcium citrate (1200 mg elementary calcium/daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Calcium carbonate (1200 mg elementary calcium/daily)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Calcium citrate
Number of subjects: 39

Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 39
Study: 27869583

Group type: EXPERIMENTAL
Intervention: Lung Age app on a first‐generation iPad
Number of subjects: 17
Study: 23225167

Group type: EXPERIMENTAL
Intervention: STOP program (N = 27)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Usual care (N = 25)
Number of subjects: 52
Study: 22465450

Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg
Number of subjects: 788

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 788
Study: 20032748

Group type: EXPERIMENTAL
Intervention: Physiotherapy (PT)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Cast
Number of subjects: 151

Group type: COMPARATOR
Intervention: Cast and Physiotherapy (PT)
Number of subjects: 151
Study: 17493562

Group type: EXPERIMENTAL
Intervention: Lunch
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Breakfast
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Study 1 (Breakfast and Lunch)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Study 2 (Boys and Girls)
Number of subjects: 225
Study: 16027399

Group type: EXPERIMENTAL
Intervention: Intravenous epoetin alfa administration
Number of subjects: 64

Group type: COMPARATOR
Intervention: Subcutaneous epoetin alfa administration
Number of subjects: 64
Study: 11933904

Group type: EXPERIMENTAL
Intervention: IRM (Type III ZOE cement) mixed at powder:liquid (P:L) ratio of 10g:2g
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: IRM (Type III ZOE cement) mixed at powder:liquid (P:L) ratio of 10g:1g
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no temporary restoration)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Poly‐carboxylate cement (eugenol‐free) mixed at a P:L ratio of 2.85g:1g
Number of subjects: 32
Study: 9880451

Group type: EXPERIMENTAL
Intervention: rhu GM‐CSF (8 microg/kg/d), administered intravenously over 2 hours daily for 7 days and every other day for 21 days
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 7720346

Group type: EXPERIMENTAL
Intervention: Total enteral nutrition (n = 21)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Total parenteral nutrition (n = 25)
Number of subjects: 46
Study: 2187723

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha (rIFN-alpha), 10 MU/m2 body surface, intramuscularly, 3 times a week for 3 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha (rIFN-alpha)
Number of subjects: 24
Study: 31875315

Group type: EXPERIMENTAL
Intervention: Conditions promoting faster performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditions promoting slower performance
Number of subjects: 0
Study: 31407827

Group type: EXPERIMENTAL
Intervention: Hangeshashinto (TJ‐14) 7.5 g/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral alkalization (sodium bicarbonate 1.8 g/day; ursodeoxycholic acid 300 mg/day)
Number of subjects: 30
Study: 29086523

Group type: EXPERIMENTAL
Intervention: Group phone-based weight management intervention
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Self-reported MVPA
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: High loss, low regain group
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Maintenance phase
Number of subjects: 142
Study: 25846144

Group type: EXPERIMENTAL
Intervention: Ledipasvir (LDV) and sofosbuvir (SOF) for 12 weeks
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Ledipasvir (LDV) and sofosbuvir (SOF) for 24 weeks
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Ledipasvir (LDV) and sofosbuvir (SOF) plus ribavirin (RBV) for 12 weeks
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Ledipasvir (LDV) and sofosbuvir (SOF) plus ribavirin (RBV) for 24 weeks
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Ledipasvir (LDV) and sofosbuvir (SOF) for 12 weeks without RBV in previously treated patients
Number of subjects: 513

Group type: COMPARATOR
Intervention: Ledipasvir (LDV) and sofosbuvir (SOF) alone
Number of subjects: 513

Group type: COMPARATOR
Intervention: Ledipasvir (LDV) and sofosbuvir (SOF) plus ribavirin (RBV)
Number of subjects: 513
Study: 23077973

Group type: EXPERIMENTAL
Intervention: Bedtime therapy with at least one hypertension medication
Number of subjects: 776
Study: 20693243

Group type: EXPERIMENTAL
Intervention: Indacaterol (150 μg once daily)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Salmeterol (50 μg twice daily)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1002
Study: 18825368

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) in patients with vasodilatory shock after cardiac surgery
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (patients undergoing uncomplicated aorto-coronary bypass surgery)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Copeptin in patients with vasodilatory shock after cardiac surgery
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: AVP response in patients with chronic angiotensin-converting enzyme inhibitor therapy
Number of subjects: 43
Study: 17052901

Group type: EXPERIMENTAL
Intervention: Isoproterenol (7.5mg/h)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Albuterol (7.5mg/h)
Number of subjects: 19
Study: 15288384

Group type: EXPERIMENTAL
Intervention: Trexan and amino-acid therapy
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Trexan without amino-acid therapy
Number of subjects: 1012
Study: 11594942

Group type: EXPERIMENTAL
Intervention: Antioxidants plus zinc (vitamin C 500 mg, vitamin E 400 IU, beta carotene 15 mg, zinc 80 mg)
Number of subjects: 3640

Group type: EXPERIMENTAL
Intervention: Zinc alone (80 mg)
Number of subjects: 3640

Group type: EXPERIMENTAL
Intervention: Antioxidants alone (vitamin C, E, beta carotene)
Number of subjects: 3640

Group type: EXPERIMENTAL
Intervention: Antioxidants plus zinc (in higher-risk group)
Number of subjects: 3640

Group type: EXPERIMENTAL
Intervention: Zinc (in higher-risk group)
Number of subjects: 3640

Group type: EXPERIMENTAL
Intervention: Antioxidants (in higher-risk group)
Number of subjects: 3640

Group type: EXPERIMENTAL
Intervention: Antioxidants plus zinc
Number of subjects: 3640

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3640
Study: 9756575

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Patch angioplasty closure
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Reoperation for recurrent stenosis
Number of subjects: 720
Study: 7923255

Group type: EXPERIMENTAL
Intervention: Aortic stenosis patients
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Aortic stenosis patients with changes in collagen architecture
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (pre-transplantation donor hearts and normal cardiac function)
Number of subjects: 27
Study: 3073804

Group type: EXPERIMENTAL
Intervention: Oral terbutaline (2.5 mg orally three times daily for a week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31315939

Group type: EXPERIMENTAL
Intervention: Ischaemic postconditioning plus primary PCI
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Conventional treatment (primary PCI)
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Conventional PCI
Number of subjects: 1234
Study: 30157911

Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity (self-report and accelerometry)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Lowest levels of lifestyle physical activity
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity
Number of subjects: 171
Study: 27624618

Group type: EXPERIMENTAL
Intervention: 6-month strength-based patient navigation interventions with contingency management (PN+CM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6-month strength-based patient navigation interventions without contingency management (PN only)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (referral to health care and SUD treatment)
Number of subjects: 0
Study: 26656336

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP) transfusion in the HAS group
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Artificial infusion solutions in the HAS group
Number of subjects: 47

Group type: COMPARATOR
Intervention: NLAS group (none or low ascites)
Number of subjects: 47

Group type: COMPARATOR
Intervention: HAS group (high ascites)
Number of subjects: 47
Study: 23299383

Group type: EXPERIMENTAL
Intervention: Daily doses of 400 IU of vitamin E and 200 µg of selenium
Number of subjects: 7547

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7547

Group type: EXPERIMENTAL
Intervention: TICS-M exam
Number of subjects: 7547
Study: 21079803

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02(D) vaccine
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 214
Study: 18042976

Group type: EXPERIMENTAL
Intervention: saline(NEB) + AD
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: saline(IPV) + AD
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: AD after saline(NEB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: AD after saline(IPV)
Number of subjects: 20
Study: 16582046

Group type: EXPERIMENTAL
Intervention: Integrated Care (IC)
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Enhanced Specialty Referral (ESR)
Number of subjects: 1052
Study: 12919649

Group type: EXPERIMENTAL
Intervention: Irbesartan treatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 72
Study: 10969114

Group type: EXPERIMENTAL
Intervention: Click test for surfactant therapy
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual clinical and chest radiograph criteria for surfactant therapy
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Click test and usual criteria
Number of subjects: 126
Study: 8993764

Group type: EXPERIMENTAL
Intervention: Transfer Factor (TF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1614101

Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate 0.1% + diclofenac 0.1% drops
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dexamethasone acetate 0.1% + placebo drops
Number of subjects: 40
Study: 6379345

Group type: EXPERIMENTAL
Intervention: Diclofensine (2 X 25 mg/day for 30 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diclofensine
Number of subjects: 40
Study: 30300405

Group type: EXPERIMENTAL
Intervention: Medial arch support foot orthoses
Number of subjects: 30

Group type: COMPARATOR
Intervention: Flat 2‐mm‐thick insoles (sham condition)
Number of subjects: 30
Study: 26610637

Group type: EXPERIMENTAL
Intervention: Laser + Ex Regime 2
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo + Ex Regime 1
Number of subjects: 80

Group type: COMPARATOR
Intervention: Laser + Ex Regime 1
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo + Ex Regime 2
Number of subjects: 80
Study: 23775007

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 22648842

Group type: EXPERIMENTAL
Intervention: Ensure
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nutrison
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Peptison
Number of subjects: 45
Study: 20174642

Group type: EXPERIMENTAL
Intervention: Community-based treatment by Health Extension Workers (HEWs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment by general health workers at health facility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based treatment by HEWs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Involving HEWs in TB treatment
Number of subjects: 0
Study: 18662202

Group type: EXPERIMENTAL
Intervention: Napping (self-reported)
Number of subjects: 414
Study: 15858317

Group type: EXPERIMENTAL
Intervention: B‐1 (slight facet with wearing of the ink but no indentation on the splint)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: B‐2 (slight indentation on the splint)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: B‐3 (notable indentation on the splint)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Restorations in B‐1, B‐2, B‐3 after 15 years
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Inlay in B‐1, B‐2, B‐3 after 15 years
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Crown in B‐1, B‐2, B‐3 after 15 years
Number of subjects: 422
Study: 14563144

Group type: EXPERIMENTAL
Intervention: 700‐cGy external‐beam irradiation to the operative site 24 hours prior to reexploration and decompressive treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: No preoperative irradiation (control group)
Number of subjects: 10
Study: 10364951

Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol (IPA) wipes before venesection
Number of subjects: 194

Group type: COMPARATOR
Intervention: No isopropyl alcohol (IPA) wipes before venesection
Number of subjects: 194
Study: 8896099

Group type: EXPERIMENTAL
Intervention: Kennedy ligament augmentation device (LAD)
Number of subjects: 82

Group type: COMPARATOR
Intervention: No augmentation (non-augmented knee group)
Number of subjects: 82
Study: 2050831

Group type: EXPERIMENTAL
Intervention: HCTZ 50 mg daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Amiloride 10 mg daily
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 6084123

Group type: EXPERIMENTAL
Intervention: guanabenz 16 mg/hydrochlorothiazide 25 mg (combination tablet)
Number of subjects: 24

Group type: COMPARATOR
Intervention: hydrochlorothiazide 25 mg (alone)
Number of subjects: 24
Study: 31722312

Group type: EXPERIMENTAL
Intervention: Intramuscular injection with E0302 50 mg, twice a week for 16 weeks
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo, twice a week for 16 weeks
Number of subjects: 128
Study: 28571119

Group type: EXPERIMENTAL
Intervention: Paliperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25299501

Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia (TH)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Historical control (no hypothermia)
Number of subjects: 21
Study: 23480216

Group type: EXPERIMENTAL
Intervention: PEG 3350+E (26 g split dose daily)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Prucalopride (1-2 mg daily)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: PEG 3350+E
Number of subjects: 240

Group type: COMPARATOR
Intervention: Prucalopride
Number of subjects: 240
Study: 21676229

Group type: EXPERIMENTAL
Intervention: Non-invasive cardiac output monitoring for 24 hours (MICO group)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Non-invasive cardiac output monitoring (MICO group)
Number of subjects: 388
Study: 19170454

Group type: EXPERIMENTAL
Intervention: MI with feedback
Number of subjects: 279

Group type: COMPARATOR
Intervention: MI without feedback
Number of subjects: 279

Group type: COMPARATOR
Intervention: Feedback alone
Number of subjects: 279

Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 279
Study: 16832133

Group type: EXPERIMENTAL
Intervention: Enteral feeding via nasojejunal tube with study feed containing glutamine, arginine, tributyrin and antioxidants for 3 days
Number of subjects: 31

Group type: COMPARATOR
Intervention: Isocaloric isonitrogenous control feed
Number of subjects: 31
Study: 15107913

Group type: EXPERIMENTAL
Intervention: EDTA gel (pH 7.0) at concentrations of 5%, 10%, 15%, 20%, and 24% (n = 100)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: EDTA-T gel (pH 7.0) at concentrations of 5%, 10%, 15%, 20%, and 24% (n = 100)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (saline solution, n = 20)
Number of subjects: 220
Study: 11707790

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (EF) - 17 mL of 2% lidocaine plus 100 microg fentanyl
Number of subjects: 36

Group type: COMPARATOR
Intervention: IV fentanyl (IF) - 17 mL of 2% lidocaine plus 2 mL of normal saline followed by IV injection of 100 microg of fentanyl
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (C) - 17 mL of 2% lidocaine plus 2 mL of normal saline followed by IV injection of 2 mL of normal saline
Number of subjects: 36
Study: 9206952

Group type: EXPERIMENTAL
Intervention: Long-term artificial pulmonary ventilation and feeding through a naso-gastric probe
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Biopsies of n. suralis taken at different periods after the appearance of the first signs of DP
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Microscopy studies (light and electronic)
Number of subjects: 18
Study: 7960161

Group type: EXPERIMENTAL
Intervention: High level interventions
Number of subjects: 1585

Group type: EXPERIMENTAL
Intervention: Medium level interventions
Number of subjects: 1585

Group type: EXPERIMENTAL
Intervention: Low level interventions
Number of subjects: 1585

Group type: EXPERIMENTAL
Intervention: Overall work effort
Number of subjects: 1585
Study: 2880213

Group type: EXPERIMENTAL
Intervention: Combination vaccine (live BCG + killed leishmania promastigotes)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard antimonial regimen (meglumine antimonate)
Number of subjects: 94
Study: 31430059

Group type: EXPERIMENTAL
Intervention: Guideline cleaning
Number of subjects: 128

Group type: COMPARATOR
Intervention: Routine cleaning
Number of subjects: 128
Study: 29255961

Group type: EXPERIMENTAL
Intervention: Double-incision laparoscopic cholecystectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional four-port laparoscopic cholecystectomy
Number of subjects: 0
Study: 27431595

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 868

Group type: COMPARATOR
Intervention: Propofol-based TIVA
Number of subjects: 868
Study: 24139497

Group type: EXPERIMENTAL
Intervention: Fluticasone/Salmeterol
Number of subjects: 611

Group type: COMPARATOR
Intervention: 2.5× Fluticasone
Number of subjects: 611

Group type: COMPARATOR
Intervention: Fluticasone/Montelukast
Number of subjects: 611

Group type: COMPARATOR
Intervention: Leukotriene Receptor Antagonist and Inhaled Corticosteroid
Number of subjects: 611
Study: 23497032

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment at 6 standard acupuncture points (ST36, ST35, ST34, SP9, Ex‐LE04, and SP10) 3 times per week for 4 weeks (total of 12 sessions)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Usual care (no moxibustion treatment)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment
Number of subjects: 212

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 212
Study: 21460709

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (0.6 mg/kg/day, 48 hrs)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 17904718

Group type: EXPERIMENTAL
Intervention: Microbicide feasibility study participation
Number of subjects: 21
Study: 16546850

Group type: EXPERIMENTAL
Intervention: TMD treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 120
Study: 12689776

Group type: EXPERIMENTAL
Intervention: Static lumbar flexion for 10 minutes
Number of subjects: 0
Study: 10891474

Group type: EXPERIMENTAL
Intervention: Diagnostic telomere length measurement using Southern blot hybridization with (TTAGGG)(4) probe
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Age-adjusted TRA reduction
Number of subjects: 59
Study: 8649241

Group type: EXPERIMENTAL
Intervention: DHA-supplemented formula (0.2% docosahexaenoic acid from marine oil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control formula (without DHA)
Number of subjects: 0
Study: 1399355

Group type: EXPERIMENTAL
Intervention: Over-tube (O-T) technique
Number of subjects: 102

Group type: COMPARATOR
Intervention: Free-hand (F-H) technique
Number of subjects: 102
Study: 3528612

Group type: EXPERIMENTAL
Intervention: Captopril or prazosin treatment in Group I patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Group I patients (elevated vasopressin)
Number of subjects: 25
Study: 29370120

Group type: EXPERIMENTAL
Intervention: VMP (dietary multivitamin, multimineral and phytonutrient supplement)
Number of subjects: 120

Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 120
Study: 27196148

Group type: EXPERIMENTAL
Intervention: Home-based physical activity and diet intervention
Number of subjects: 401
Study: 24874533

Group type: EXPERIMENTAL
Intervention: Facet corticosteroid injections
Number of subjects: 56

Group type: COMPARATOR
Intervention: Transforaminal corticosteroid injections
Number of subjects: 56
Study: 22398670

Group type: EXPERIMENTAL
Intervention: Edema index-guided case management (EI)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 159

Group type: COMPARATOR
Intervention: Case management (CM)
Number of subjects: 159
Study: 20639746

Group type: EXPERIMENTAL
Intervention: High-frequency percussive ventilation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Low-tidal volume ventilation
Number of subjects: 62
Study: 18716158

Group type: EXPERIMENTAL
Intervention: MUFA-rich diet (38% total fat, 22% MUFA)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: CHO-rich diet (30% total fat, 55% carbohydrate)
Number of subjects: 59

Group type: COMPARATOR
Intervention: SFA-rich diet (38% total fat, 20% SFA)
Number of subjects: 59

Group type: COMPARATOR
Intervention: C/C women
Number of subjects: 59
Study: 17142217

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg intravenously before surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: No medication administered (Control)
Number of subjects: 30
Study: 12692753

Group type: EXPERIMENTAL
Intervention: Benazepril (ACE inhibitor)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Valsartan (ARB)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Benazepril plus Valsartan (combination therapy)
Number of subjects: 36
Study: 10750754

Group type: EXPERIMENTAL
Intervention: Standard heparinization (group S; 300 IU/kg initially; ACT > 480 seconds; 5,000 IU in prime)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reduced heparinization (group R; 100 IU/kg initially; ACT > 250 seconds; 2,500 IU in prime)
Number of subjects: 30